Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab - PubMed (original) (raw)
Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab
Malte von Bonin et al. Transplantation. 2008.
Abstract
Rituximab, an anti-CD20 chimeric monoclonal antibody, is widely used in hematologic malignancies and has been introduced as a therapeutic option in autoimmune disorders. In recent studies, rituximab has shown promising activity in steroid-refractory chronic graft-versus-host disease (cGvHD) at a weekly dose of 375 mg/m2. We now report on 13 subjects after peripheral blood stem-cell transplantation receiving low-dose rituximab (50 mg/m2) for steroid-refractory cGvHD and autoimmune disorders (membranous glomerulonephritis and immune thrombocytopenic purpura). The overall response rate was 69%, including two patients with complete responses. In accordance, we observed clearance of peripheral blood B cells even after the first dose of rituximab in four patients. We conclude that low-dose rituximab seems to be active and safe in intensively pretreated patients with steroid-refractory cGvHD.
Similar articles
- Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS, Engemann AM, Hammond JM. Bates JS, et al. Ann Pharmacother. 2009 Feb;43(2):316-21. doi: 10.1345/aph.1L386. Epub 2009 Feb 3. Ann Pharmacother. 2009. PMID: 19193571 Review. - Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC. Braendstrup P, et al. Am J Hematol. 2005 Apr;78(4):275-80. doi: 10.1002/ajh.20276. Am J Hematol. 2005. PMID: 15795920 - B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R. Zaja F, et al. Haematologica. 2002 Feb;87(2):189-95. Haematologica. 2002. PMID: 11836170 Clinical Trial. - Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Zaja F, et al. Bone Marrow Transplant. 2007 Aug;40(3):273-7. doi: 10.1038/sj.bmt.1705725. Epub 2007 Jun 4. Bone Marrow Transplant. 2007. PMID: 17549053 - Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA, Bazarbachi A. Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant. 2010 Oct;16(10):1347-54. doi: 10.1016/j.bbmt.2010.01.005. Epub 2010 Jan 18. Biol Blood Marrow Transplant. 2010. PMID: 20083213 Review.
Cited by
- Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Yang K, Chen Y, Qi H, Ye Y, Fan Z, Huang F, Zhang H, Suo Y, Liu Q, Jin H. Yang K, et al. Front Immunol. 2020 Jul 28;11:1505. doi: 10.3389/fimmu.2020.01505. eCollection 2020. Front Immunol. 2020. PMID: 32849514 Free PMC article. - Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation.
Chinello M, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Tonin P, Vattemi G, Guglielmi V, Cesaro S. Chinello M, et al. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020002. doi: 10.4084/MJHID.2020.002. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 31934312 Free PMC article. - The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.
Rhoades R, Gaballa S. Rhoades R, et al. Biomedicines. 2017 Oct 17;5(4):61. doi: 10.3390/biomedicines5040061. Biomedicines. 2017. PMID: 29039818 Free PMC article. Review. - Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.
Johnston HF, Xu Y, Racine JJ, Cassady K, Ni X, Wu T, Chan A, Forman S, Zeng D. Johnston HF, et al. Biol Blood Marrow Transplant. 2014 Aug;20(8):1089-103. doi: 10.1016/j.bbmt.2014.04.028. Epub 2014 May 4. Biol Blood Marrow Transplant. 2014. PMID: 24796279 Free PMC article. - Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.
Van Hoef ME. Van Hoef ME. Haematologica. 2013 Apr;98(4):e40-1. doi: 10.3324/haematol.2012.082271. Haematologica. 2013. PMID: 23543154 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical